Zobrazeno 1 - 10
of 203
pro vyhledávání: '"MESH : Antineoplastic Combined Chemotherapy Protocols"'
Autor:
Sophie Abadie-Lacourtoisie, Thierry Nguyen-Tan-Hon, Jean-Philippe Spano, Olivier Huillard, Nadine Houede, Hakim Mahammedi, Eric Voog, Yohann Loriot, Tifenn Lharidon, Sheik Emambux, Stéphane Culine, Lionnel Geoffrois, Jean-Christophe Eymard, Mounira El Demery, V. Harter, Vesper Trial Investigators, Philippe Barthélémy, Brigitte Laguerre, Yves Allory, Christine Chevreau, Aline Guillot, Florence Joly, Frédéric Di Fiore, Carolina Saldana, Gwenaelle Gravis, Christian Pfister, Werner Hilgers, Camille Serrate, Guilhem Roubaud, Sabine Vieillot, Aude Fléchon, Frederic Rolland
Publikováno v:
Clinical Genitourinary Cancer
Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩
Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩
Background : Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date. Patients and Methods : In the VESPE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d9aa8d1b02aa6db6c212d2664180052
https://doi.org/10.1016/j.clgc.2021.08.005
https://doi.org/10.1016/j.clgc.2021.08.005
Autor:
John Wrangle, Ticiana Leal, Gilles Robinet, Neal Ready, David Maag, Jyoti Malhotra, Melissa Lynne Johnson, Satwant Lally, Petros Nikolinakos, Jyoti D. Patel, Daniel Morgensztern, Benjamin Besse, Vincent Blot, Giuseppe Curigliano, Ricardo Valenzuela, Laurent Greillier, Jonathan M. Lehman
Publikováno v:
Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2021, 16 (9), pp.1559-1569. ⟨10.1016/j.jtho.2021.02.022⟩
Journal of Thoracic Oncology, 2021, 16 (9), pp.1559-1569. ⟨10.1016/j.jtho.2021.02.022⟩
Introduction This open-label, phase 1–2 study evaluated the safety and efficacy of rovalpituzumab tesirine (Rova-T), an antibody-drug conjugate targeting DLL3, plus immune checkpoint inhibitors nivolumab plus or minus ipilimumab in previously treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7c2323534cecd409bf8ef57951bfa24
https://doi.org/10.1016/j.jtho.2021.02.022
https://doi.org/10.1016/j.jtho.2021.02.022
Autor:
Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (32), pp.3699-3708. ⟨10.1200/JCO.21.02179⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, In press, ⟨10.1200/JCO.21.02179⟩
Bachelot, T, Cottu, P, Chabaud, S, Dalenc, F, Allouache, D, Delaloge, S, Jacquin, J-P, Grenier, J, Venat Bouvet, L, Jegannathen, A, Campone, M, Del Piano, F, Debled, M, Hardy-Bessard, A-C, Giacchetti, S, Mouret-Reynier, M-A, Barthelemy, P, Kaluzinski, L, Mailliez, A, Legouffe, E, Sephton, M, Bliss, J, Canon, J-L, Penault-Llorca, F, Lemonnier, J, Cameron, D A & Andre, F 2022, ' Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer ', Journal of Clinical Oncology, vol. 386, JCO.21.02179 . https://doi.org/10.1200/JCO.21.02179, https://doi.org/10.1200/JCO.21.02179
Journal of Clinical Oncology, 2022, 40 (32), pp.3699-3708. ⟨10.1200/JCO.21.02179⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, In press, ⟨10.1200/JCO.21.02179⟩
Bachelot, T, Cottu, P, Chabaud, S, Dalenc, F, Allouache, D, Delaloge, S, Jacquin, J-P, Grenier, J, Venat Bouvet, L, Jegannathen, A, Campone, M, Del Piano, F, Debled, M, Hardy-Bessard, A-C, Giacchetti, S, Mouret-Reynier, M-A, Barthelemy, P, Kaluzinski, L, Mailliez, A, Legouffe, E, Sephton, M, Bliss, J, Canon, J-L, Penault-Llorca, F, Lemonnier, J, Cameron, D A & Andre, F 2022, ' Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer ', Journal of Clinical Oncology, vol. 386, JCO.21.02179 . https://doi.org/10.1200/JCO.21.02179, https://doi.org/10.1200/JCO.21.02179
PURPOSE Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor–resistant metastatic breast cancer. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574c2bb7629f4cc70b7bae1bbc69bd0b
https://hal.archives-ouvertes.fr/hal-03857432
https://hal.archives-ouvertes.fr/hal-03857432
Autor:
Fabrice Barlesi, Laure Deyme, Diane-Charlotte Imbs, Elissa Cousin, Mathieu Barbolosi, Sylvanie Bonnet, Pascale Tomasini, Laurent Greillier, Melissa Galloux, Albane Testot-Ferry, Annick Pelletier, Nicolas André, Joseph Ciccolini, Dominique Barbolosi
Publikováno v:
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 2022, 90 (2), pp.149-160. ⟨10.1007/s00280-022-04455-x⟩
Cancer Chemotherapy and Pharmacology, 2022, 90 (2), pp.149-160. ⟨10.1007/s00280-022-04455-x⟩
A phase Ia/Ib trial of metronomic oral vinorelbine (MOV) driven by a mathematical model was performed in heavily pretreated metastatic Non-Small Cell Lung Cancer or Pleural Mesothelioma patients. Disease Control Rate, progression free survival, toxic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f34379e61159ac5c5cbc8be9e082bc3
https://inria.hal.science/hal-03923667
https://inria.hal.science/hal-03923667
Autor:
Yann-Alexandre Vano, Réza Elaidi, Mostefa Bennamoun, Christine Chevreau, Delphine Borchiellini, Diane Pannier, Denis Maillet, Marine Gross-Goupil, Christophe Tournigand, Brigitte Laguerre, Philippe Barthélémy, Elodie Coquan, Gwenaëlle Gravis, Nadine Houede, Mathilde Cancel, Olivier Huillard, Philippe Beuzeboc, Laure Fournier, Arnaud Méjean, Xavier Cathelineau, Nicolas Doumerc, Philippe Paparel, Jean-Christophe Bernhard, Alexandre de la Taille, Karim Bensalah, Thibault Tricard, Thibaut Waeckel, Géraldine Pignot, Elena Braychenko, Stefano Caruso, Cheng-Ming Sun, Virginie Verkarre, Guillaume Lacroix, Marco Moreira, Maxime Meylan, Antoine Bougouïn, Letuan Phan, Christelle Thibault-Carpentier, Jessica Zucman-Rossi, Wolf Herman Fridman, Catherine Sautès-Fridman, Stéphane Oudard
Publikováno v:
Lancet Oncology
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩
Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩
International audience; Background: We previously reported a 35-gene expression classifier identifying four clear-cell renal cell carcinoma groups (ccrcc1 to ccrcc4) with different tumour microenvironments and sensitivities to sunitinib in metastatic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a85c6d4558df8a8fb1a475ca37c2014
https://hal.science/hal-04072026
https://hal.science/hal-04072026
Autor:
Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Elodie Negre, Gérard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Céline Mascaux, Denis Moro-Sibilot, François Pinquie, Alexis B. Cortot, Josiane Otto, Jacques Cadranel, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse
Publikováno v:
Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (7), pp.719-728. ⟨10.1200/JCO.21.01455⟩
Journal of Clinical Oncology, 2022, 40 (7), pp.719-728. ⟨10.1200/JCO.21.01455⟩
PURPOSE HER2 exon 20 insertions and point mutations are oncogenic drivers found in 1%-2% of patients with non–small-cell lung cancer (NSCLC). No targeted therapy is approved for this subset of patients. We prospectively evaluated the effectiveness
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5e269f82f648e89333d7473fc50216
https://hal.science/hal-03925605
https://hal.science/hal-03925605
Autor:
Didier Debieuvre, Pierre-Jean Souquet, Jean-Louis Pujol, Jérôme Dauba, Jeannick Madelaine, Olivier Molinier, J. Otto, Jacques Le Treut, Fabrice Barlesi, Elisabeth Quoix, Patrick Aldo Renault, Eric Pichon, Alexandra Langlais, Virginie Westeel, L. Moreau, Franck Morin, Jacques Margery, Clarisse Audigier-Valette, Armelle Lavolé, Patrick Dumont, Denis Moro-Sibilot
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
European Journal of Cancer, Elsevier, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
European Journal of Cancer, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
European Journal of Cancer, Elsevier, 2020, 138, pp.193-201. ⟨10.1016/j.ejca.2020.07.034⟩
International audience; Purpose: Maintenance chemotherapy is a reasonable choice for patients with metastatic non-small cell lung carcinoma (NSCLC) not progressing after induction therapy with a platinum-based doublet. Nevertheless, there have been n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c034c6fffdebcc9111506c34b7f426b
https://doi.org/10.1016/j.ejca.2020.07.034
https://doi.org/10.1016/j.ejca.2020.07.034
Autor:
P, Blanchard, J, Biau, F, Huguet, S, Racadot, C, Berthold, S, Wong-Hee-Kam, M-C, Biston, P, Maingon
Publikováno v:
Cancer/Radiothérapie
Cancer/Radiothérapie, 2022, 26 (1-2), pp.168-173. ⟨10.1016/j.canrad.2021.08.009⟩
Cancer/Radiothérapie, 2022, 26 (1-2), pp.168-173. ⟨10.1016/j.canrad.2021.08.009⟩
International audience; Nasopharyngeal cancers are a rarity in France. Radiotherapy is the cornerstone of treatment, frequently combined with chemotherapy. The technical modality of radiotherapy is complex in this disease, which is located in the vic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19331b60b6dc5f01c70a83139dc1b2d
https://hal.archives-ouvertes.fr/hal-03889546
https://hal.archives-ouvertes.fr/hal-03889546
Publikováno v:
B-ENT
B-ENT, 2021, 12 (1), pp.29-32
ResearcherID
Europe PubMed Central
B-ENT, 2021, 12 (1), pp.29-32
ResearcherID
Europe PubMed Central
To preoperatively reduce tumour size in patients with locally advanced and/or non-resectable squamous cell carcinoma with induction chemotherapy in order to achieve surgical excision with clear margins and preserve quality of life.In this study, 16 p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b8d339d7f4d1efffb3bc64236ad5fa7c
https://hal.archives-ouvertes.fr/hal-03439029
https://hal.archives-ouvertes.fr/hal-03439029
Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass
Autor:
Alexane Lere‐Chevaleyre, Maureen Bernadach, Céline Lambert, Lucie Cassagnes, Mathilde Puechmaille, Thierry Mom, Laurent Gilain, Michel Lapeyre, Yves Boirie, Julian Biau, Nicolas Saroul
Publikováno v:
Head & Neck
Head & Neck, 2022, 44 (3), pp.681-690. ⟨10.1002/hed.26954⟩
Head & Neck, Wiley, 2022, 44 (3), pp.681-690. ⟨10.1002/hed.26954⟩
Head & Neck, 2022, 44 (3), pp.681-690. ⟨10.1002/hed.26954⟩
Head & Neck, Wiley, 2022, 44 (3), pp.681-690. ⟨10.1002/hed.26954⟩
International audience; Background To assess the impact of nutritional status on tolerance to induction chemotherapy by docetaxel, cisplatin and 5-fluorouracil (ICT) in head and neck cancer (HNC). Methods Ninety-two HNC patients were included. Toxici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab1022a70ba3ac254d1195313be3946d
https://pubmed.ncbi.nlm.nih.gov/34918416
https://pubmed.ncbi.nlm.nih.gov/34918416